Baird Initiates Coverage on Amedisys (AMED) with a Outperform
More News related to AMED
- Amedisys to Present at the 27th Annual J.P. Morgan Healthcare Conference
- XplosiveStocks.com: AMED, EQIX, PCLN, RIMM, IDEV, JAVA Hot Stocks on the Move
- Morning Movers 1/06: Indevus Pharmaceuticals (IDEV) Soars On Buyout, Garmin (GRMN) Lower on Downgrade
- BenchmarkJournal.com (Complimentary) Analyst Review for IDEV, AMED, ENDP and CIEN
- Amedisys (AMED) Issues Strong '09 Guidance
More News related to New Coverage
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
- Wedbush Morgan Maintains a 'Buy' on ON Semiconductor (ONNN), Raises Price Target
- Analyst Round-Up: Intuitive Surgical (ISRG) - 3 Downgrades, 2 Price Target Cuts
Baird initiates coverage on Amedisys (Nasdaq: AMED) with a Outperform, saying shares currently offer compelling entry point. Price target $68.
Amedisys, Inc. (Amedisys) is a provider of home health services to the chronic, co-morbid, aging American population.
Related Categories
New CoverageStocks Mentioned
-1.91Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
